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Pulmonary large-cell neuroendocrine carcinoma (LCNEC) has been characterized by highly
aggressive behavior, with early spread to both regional lymph nodes and distant sites and a
rapidly fatal course. In fact, no reports have described an advanced pulmonary LCNEC
patient who has had long-term survival. A patient with large-sized pulmonary LCNEC, who
is free of disease 11 years after surgery and postoperative chemotherapy, was reported.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Clinically, pulmonary large-cell neuroendocrine carcinoma
(LCNEC) has been characterized by highly aggressive
behavior, with early spread to both regional lymph nodes
and distant sites and a rapidly fatal course.1–3 In fact, there
is not a single report of long-term follow-up of a patient with
advanced pulmonary LCNEC. This report describes an 11-
year disease-free survival in a patient with large-sized
locally advanced pulmonary LCNEC.Elsevier Ltd. All rights reserved.
853 3210;
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A 55-year-old male patient was admitted to our hospital
because of a large mass lesion that was detected incidentally
by a chest radiograph. He had smoked 30 cigarettes per day for
35 years. Routine blood examination and serum tumor marker
including neurons-specific enolase (NSE) was within normal
range. The patient was totally asymptomatic with unremarkable
physical examination. Chest CTscan revealed a 75 55 40mm
nodule in right lower lobe of the lung (Fig. 1). CT also showed
hilar lymph node swelling. Spirometry showed forced expiratory
volume in 1 s of 2.05L (62.1% predicted) and forced vital
capacity of 3.38L (97.4% predicted). Non-small cell lung cancer
was suspected through transbronchial biopsy, but a definitive
diagnosis could not be made before the surgery. Therefore,
surgical treatment was selected because there were no distant
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Figure 1 Chest CT scan revealed a large-sized nodule measur-
ing 75 55 40mm in the right lower lobe.
Figure 2 The tumor was characterized by large, polygonal-
shaped cells with relatively abundant cytoplasm. Rosette- and
palisading-like structures were present focally.
G. Ohara et al.2426metastases in the preoperative findings. Right lower lobectomy
with mediastinal lymph nodal dissection was performed, and
postoperative course was uneventful.
At microscopic analysis, the tumor was characterized by
large, polygonal-shaped cells with relatively abundant
cytoplasm. Rosette- and palisading-like structures were
present focally, and centrally located focal necrosis in the
tumor was observed (Fig. 2). Mitotic counts were 20 per 10
high-power fields. Immunohistochemistry showed positive
staining for CD 56, Synaptophysin, and chromogranin A.
Pathologically, the tumor stage proved to be T3N1M0, and at
the time of postoperative diagnosis was atypical carcinoid.
Thereafter, the patient received two cycles of che-
motherapy with cisplatin and 5-fluorouracil. The patient is
free of disease 11 years after surgery and postoperative
chemotherapy.Discussion
We report an 11-year survivor who presented with large-
sized locally advanced pulmonary LCNEC, which wasformally diagnosed as an atypical carcinoid. Pulmonary
LCNEC was first proposed in 1991 by Travis et al.4 and has
been newly listed in the latest WHO classification of lung
tumors.5 Diagnosis of LCNEC requires histological and
cytological evaluation, and immunohistochemical analysis.5
Accordingly, diagnosis through transbronchial biopsy may be
difficult. In the majority of patients, symptoms at presenta-
tion included cough, chest pain, hemoptysis, and dys-
pnea.3,6,7 At the time of presentation, however, some
patients were asymptomatic and tumors were picked up
incidentally on chest radiographs.3,6,8 Radiologic features of
pulmonary LCNEC are peripherally located pulmonary
nodule or mass with or without lymphadenopathy.7 But
some LCNECs have been reported as occurring in central
lesions.4 Oshiro et al.9 described that pulmonary LCNEC
usually appeared as a well-defined and lobulated tumor with
no air-bronchograms or calcification. Shin et al.7 reported
that all masses were round or ovoid with lobulated margin.
In 8 of 11 pulmonary LCNEC patients reported by Jung
et al.,10 tumor necrosis was seen on CT. In the case
described here, the large pulmonary mass in the right
middle lobe had the characteristic CT findings of pulmonary
LCNEC such as lobulation and spiculation, and tumor
necrosis. With regard to the tumor size, Rossi et al.11
described that the median diameter of their 83 pulmonary
LCNECs was 40mm (mean, 41mm; range, 10–90mm). Shin
et al.7 reported that the mean diameter of the lesion was
34mm (range 20–50mm). In 11 pulmonary LCNEC patients
reported by Jung et al., the size of the tumor ranged
13–86mm (mean 50mm) in the greatest diameter on CT.10
Most reported occurrences therefore tend to involve
relatively large tumors, often with a poor outcome
associated with the aggressive biologic behaviors.1 Our case
presented here was evaluated as one of the largest
pulmonary LCNECs in the medical literature.
According to the previous reports, the cornerstone of
therapy for pulmonary LCNEC is surgery alone or surgery
combined with chemotherapy.1–3,11–13 Initially, we evalu-
ated the tumor as locally advanced atypical carcinoid and
administrated postoperative chemotherapy in the hope of
controlling microscopic distant metastases. This patient
probably did not have distant metastases despite the
presence of regional lymph node spread. Based on the
reported experience with pulmonary LCNEC, this pattern of
spread is distinctly unusual, as the great majority of patients
with spread to lymph nodes also have distant sites of
metastases. Our patient did receive two cycles of che-
motherapy with cisplatin and 5-fluorouracil, raising the
possibility that occult distant metastases were successfully
treated with the postoperative chemotherapy as a salutary
effect. To our knowledge, this is the first case report of
apparent cure (11-year survival) of a patient with large-
sized pulmonary LCNEC metastatic to regional lymph nodes.
LCNECs have been reported as occurring in either peripheral
or central lesions.4 However, there has been no reliable data
that can help us evaluate whether peripherally located
LCNECs have more favorable prognosis or not. Whereas, the
markedly better survival in our patient may be caused by
some other factors. Aforementioned unusual spread pattern
may be one of the factors. Survival may be influenced by the
extent of complete anatomical resection and systematic
nodal dissection, which were evaluated as the best
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Long-term survivor with LCNEC 2427treatment for LCNEC by Zacharias et al.3 Postoperative
chemotherapy may also have a role in prolonged survival in
our patient.
Locoregional control was achieved using an aggressive
combined modality approach consisting of surgery and
postoperative chemotherapy. Although it is difficult to make
firm conclusions based on such a limited experience, this
tumor appears to require an aggressive combined modality
approach using surgery for locoregional control and systemic
chemotherapy for distant control. This report demonstrates
that long-term survival can be achieved in the presence of
regional lymph node metastases and suggests that successful
treatment is dependent on use of a combined modality
approach.
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